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ABSTRACT 
 
Objectives : This study is to compare  between Cystatin C and 24 hour urine creatinine 
clearance for detection of renal impairment in hypertensive pregnancies population. 
 
Study Methods:  64 patients enrolled in this cross sectional study and each patient was required 
to collect 24 hour urine and 15 mls of blood. Blood taking was taken once in second and third 
trimester. Urine collection was carried out during the first visit. Creatinine clearance below 90 
mls/min is taken as renal impairment and compared to the serum Cystatin C level. The Receiver 
Operating Characteristic Curve is drawn to obtain the sensitivity and specificity of Cystatin C.  
 
Results : The results have shown that when compared to 24 hour urine creatinine clearance,  in 
second trimester, Cystatin C is 84.6 % sensitive and 86.7%  specific for detection of renal 
impairment at Cystatin C level of 0.574-0.898 (p value < 0.012) , area under curve: 0.736, 
positive predictive value is 0.92 and negative predictive value is 0.76.  While in the third 
trimester, the sensitivity and specificity is 76.9% and 60% at the Cystatin C level of 0.657-1.00 
(p value < 0.006), area under curve 0.838, the positive predictive value is 0.71 and negative 
predictive value is 0.67.  
 
Conclusion: Our study suggests that Cystatin C is a useful diagnostic kit for diagnosis of renal 
impairment in hypertensive pregnancies population. 
 
 
ABSTRAK 
 
Objektif: Kegagalan fungsi buah pinggang wanita hamil yang mempunyai tekanan darah tinggi 
dapat dikenalpasti dengan ujian Cystatin C. Ia dibandingkan dengan ujian air kencing ‘creatinine 
clearance’ 24 jam.  
 
Metodologi: Seramai 64 pesakit terlibat didalam kajian ini. Sampel air kencing dikumpulkan 
selama 24 jam dan pengambilan darah 15 ml diperlukan. Darah pesakit diambil pada trimester 
kedua dan ketiga. Manakala air kencing 24 jam diambil pada lawatan pertama. Nilai ‘Creatinine 
clearance’ kurang daripada 90 ml/min menunjukkan kegagalan fungsi buah pinggang dan ini 
dibandingkan dengan paras Cystatin C. Graf ‘Receiver Operating Characteristic Curve’ untuk 
mendapatkan sensitiviti dan spesifisiti Cystatin C dilakarkan. 
 
Keputusan: Keputusan dibandingkan dengan ujian air kencing ‘creatinine clearance’ 24 jam. 
Trimester kedua menunjukkan Cystatin C adalah 84.6% sensitif dan 86.7% spesifik, dalam 
mengesan kegagalan fungsi buah pinggang. Paras Cystatin C adalah  0.574-0.898  (nilai p< 
0.012) ,‘area under curve’ adalah 0.736. Manakala ‘nilai prediktif  positif’ ialah 0.92 dan ‘nilai 
prediktif negatif’ ialah 0.76. Pada trimester ketiga, sensitiviti dan spesifisiti adalah 76.9% dan 
60% masing-masing. Paras Cystatin C  0.657-1.000 (nilai p<0.006), ‘area under the curve’ 
adalah 0.838, ‘nilai prediktif positif’ ialah 0.71 dan ‘nilai prediktif negatif’ ialah 0.67.  
 
Kesimpulan: Kajian ini menunjukkan Cystatin C berguna dalam mendiagnosa kegagalan fungsi 
buah pinggang kepada wanita hamil yang mempunyai tekanan darah tinggi.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
INTRODUCTION
CHAPTER 1 
INTRODUCTION 
 
 
1.1 Renal impairment in hypertensive pregnancies – morbidities and mortalities  
Kidney is an important organ in maintaining physiology of pregnancy. Pregnancy related acute 
renal failure predisposes the pregnancy to multiple medical risks, thus increased morbidity and 
mortality (Brown et al., 2001). Preeclampsia and uncontrolled hypertension are recognized 
factors causing renal impairment. In third world countries pregnancy causes 25% of acute kidney 
injury and maternal mortality rate ranges from 9-55% (Prakash et al., 1995). Preeclampsia 
increases maternal morbidity and mortality.  Renal impairment is associated in hypertensive 
pregnancies (Chee, 1988) .  Early detection of renal impairment in hypertensive pregnancies 
enable immediate referral and multidisciplinary approach. Consequently further deterioration of 
kidney function is preventable. Diagnostic tools with high sensitivity and acceptable specificity 
is important for renal function assessment (Hoek et al., 2003).  
 
Preeclampsia and eclampsia constitutes 75% as the cause of acute kidney injury in pregnancy, 
while sepsis 11% and followed by hemorrhage 7.2%. Fetal death was reported at 5.5 % while 
maternal death at 9.1% (Silva et al., 2009). Another study conducted in India, discovered 
maternal mortality due to pregnancy related acute renal failure was 24.3% (Misra et al., 2003). 
   
Perinatal mortality rate is significantly higher with Glomerular Filtration Rate (GFR) of 70 
ml/min. A consistent observation showing that serum creatinine >2.5 mg/dl (220 µmol/l) is 
associated with more preterm deliveries and lower birth weights than women with a lower serum 
creatinine. 73% of such women were delivered before 37 weeks and 57% had intra-uterine 
growth retardation (Knutzen and Davey, 1977) 
 
. 
1.2. Current available measures in detection of chronic kidney disease 
Several investigations available in diagnosing kidney impairment. Investigations are divided to 
urine, blood, radiological investigation and renal biopsy. Urine analysis include urine for 
microalbumin, protein and hematuria. Radiological investigations include, ultrasonography of 
the kidneys, X-ray of the kidney, ureter and bladder, radionuclide imaging Diethylene Triamine 
Penta-acetic acid (DTPA),  Dimercaptosuccinic acid (DMSA)  scan. Renal biopsy is carried out 
in exclusive conditions, and general indications include assessment of causes of proteinuria and 
for identifying the cause of acute glomerulonephritis.  Blood investigations include serum 
creatinine and urea level. 24 hour urine creatinine clearance is another method requiring patient 
to collect 24 hours urine sampling and blood for serum creatinine taken simultaneously. 
 
1.2.1. Urine Analysis  
Urine analysis is performed as initial assessment in any patients presented with renal failure. 
Indications include confirmation and diagnosis of proteinuria, urinary tract infection, and 
establishing the cause of acute renal failure. There is no contraindication for the test and it can be 
performed routinely by the bedside. The test is cheap and readily available. Urine phase contrast 
is another tool available in urinalysis to detect glomerular injury. However this test can only be 
performed in centers with the facility and trained staff. These investigations depend on the 
quality of the sample taken, uncooperative patient is a disadvantage (Hou and Peano, 1998). 
Sensitivity and specificity of the test depends upon the laboratory and quality of the sample 
collected. 
 
1.2.2.  24 hour urine creatinine clearance 
24 hour endogenous creatinine clearance is employed as it is widely available in any laboratory 
facilities. However the reliability of this method is diminished by patient’s accuracy in collecting 
timed urine sample and tubular variability creatinine secretion. This method requires patient to 
be present once to the clinic for sample collection and blood taking. Inadequate urine volume 
may result in underestimation of kidney function (Johnson, 2005). Other factors that may affect 
its accuracy include prolonged urine storage may cause deranged urine creatinine levels. High 
temperature and acidified urine will cause more conversion of creatine to creatinine. 
Multiplication of urinary bacterial colony especially contributes to the changes of urine pH. 
Drugs like cimetidine inhibits tubular secretion of creatinine, therefore improves its accuracy . 
Unfortunately, variability in  individual response to this method has been observed. In cases of 
oliguric or anuric acute kidney injury this method may not be suitable. This method is taken as 
the ‘gold standard’ and under appropriate instruction to the patient will reduce the chances of 
inaccuracy. Inulin clearance, even though is the most accurate method of assessing creatinine 
clearance , is not applicable in day-to-day clinical practice (Brown et al., 2001) .  
 
1.2.3. Blood investigations 
There are numerous blood investigations available in assessment of renal failure. Conventionally 
serum creatinine and blood urea are widely and readily available throughout the country. 
Indications of these tests mainly to establish the diagnosis of renal failure. The sensitivity and 
specificity of these tests depends upon the clinical situation. Serum creatinine is very useful in 
determining the GFR. However certain drugs such as cimetidine, an H2 antagonists inhibits 
tubular secretion of creatinine causing it to be falsely high in blood. Serum creatinine value is 
reproducible for Chronic Kidney Disease Staging (CKD staging). It is particularly useful in risks 
stratification of patients with renal failure in specific clinical situation. For example in pregnancy 
related acute renal failure, decisions to sustain or terminate the pregnancy will depend on the 
clinical staging of the renal impairment. CKD staging is classified to 5 clinical stages. Stage I is 
creatinine clearance above 90 mls/min, Stage II between 60 to 89 mls/min,  Stage III between 30 
to 59 mls/min, Stage IV between 15 to 29 mls/min and Stage V below 15 mls/min (K/DOQI, 
2004). 
 
1.2.4. Radiological Investigation 
Radiological investigations are performed to identify aetiology of the renal impairment or 
supporting the diagnosis. Investigations are divided to invasive and non-invasive. Invasive 
investigations include computerized tomography (CT) angiogram, magnetic resonance 
angiography and intravenous pyelography. These investigations include the use of contrast media 
and carries risks of contrast induced nephropathy and allergic reactions. Magnetic resonance 
angiography exposes patient to nephrogenic systemic fibrosis. Non-invasive investigations 
include ultrasonography and Kidney Ureter Bladder (KUB) x-ray. However, non-radioopaque 
will not be visible in this investigation. Indications for CT scan include in renal vein thrombosis, 
renal artery stenosis and renal infarction.  CT urography is indicated in cases of obstructive 
uropathy to identify the level of obstruction. Contraindications for these investigations would 
include hypersensitivity to contrast media. 
1.2.5. Renal Biopsy 
Renal biopsy is performed under local anesthesia, via posterior approach. The procedure is 
invasive and ultrasound guided. This procedure is  indicated in unexplained state of acute or 
chronic kidney disease with normal renal size kidneys. The histopathological finding will help to 
assist the management of these patients. Information regarding the disease activity can also be 
obtained from this tissue diagnosis. Contraindications for this procedure include small size 
kidneys, multiple cysts, suspected renal tumor, hydronephrosis, urinary tract infection, bleeding 
tendencies and uncooperative patients. Renal biopsy is technically difficult and carries 
complications in pregnant ladies. Schewitz et al., (1965) describes gross hematuria in 16.7% of 
77 pregnant women, 4.4 % developed perirenal hematoma and one death. 
 
Contraindication for renal biopsy include small kidney size, bipolar length less than 9cm, single 
kidney, coagulopathy, uncooperative patient and ongoing urinary tract infection. 
 
1.2.6. Protein Creatinine Index Ratio And Albumin  Creatinine Ratio 
Normally, daily protein excretion does not exceed 150 mg, most filtered protein is reabsorbed. 
Proteinuria is a marker of nephropathy, gross proteinuria as in nephritic range suggest overt 
nephropathy. However proteinuria slightly increased in healthy pregnancy, levels above 
260mg/24 hours considered abnormal. Conventionally 24 hour urine collection is used to 
quantify total 24 hour urine excretion, however this method  requires patient to present twice to 
the clinic and to follow the instructions. It is bound to inaccuracy. Alternatively protein 
creatinine ratio can be used, it has good correlation with 24 hour urine protein collection. 
 
1.2.7 Gold Standard Test For Diagnosis Of Renal Impairment 
Inulin clearance has been  recognized as the gold standard for assessment of renal function. The 
test which determines GFR is not feasible to be carried out in the clinical setting. Even though 
the investigation has high accuracy unfortunately it is tedious and requires continuous infusion of 
inulin and serial blood taking from the patients. The investigation is mainly been carried out in 
experimental laboratories (Locatelli et al., 2002). 
 
1.3. Pathophysiology of renal impairment  in hypertensive pregnancies 
Renal impairment in pregnancies is multifactorial and maybe preexisted or contributory to the 
pregnancy. Physiological renal adaptation is a natural process and important in sustaining the 
pregnancy and ensuring the maternal and fetal outcome. Failure of this natural mechanism 
resulted in homeostasis imbalance and fetal or maternal loss. There are numerous other causes of 
renal impairment in pregnancy but hypertension is common and early detection and appropriate 
management may improve the outcome. Hypertensive disorders are major cause of maternal 
mortality, accounting 20% of maternal death (Bosio et al., 1999). Most deaths occur in women 
with eclampsia and severe hypertension and are due to intracerebral hemorrhage (Atlas of 
Kidney Disease, 2007). 
 
The pathophysiology of hypertension in pregnancy is postulated from preeclampsia which later 
resulted in renal hypoperfusion and prerenal failure. The major mechanism is widespread 
vascular endothelial dysfunction resulting in vasospasm, intravascular coagulation, hypertension, 
renal, hepatic and central nervous system abnormalities (Hladunewich et al., 2007). 
Abnormalities in uteroplacental circulation and release of toxic substances affecting the maternal  
endothelial  cells. Endothelial cell dysfunction results in increased platelet aggregation  leading 
to widespread systemic vasospasm, intravascular coagulation and decreased organ flow. 
 
In normal pregnancy, the placenta involves transformation of the branches of maternal uterine 
arteries, the spiral arteries from thick walled muscular arteries into saclike flaccid vessels that 
permit delivery of greater volume of blood to the uteroplacental unit (Dunlop, 1981). 
 
In preeclampsia, the process is incomplete, resulting in narrowed spiral arteries and decreased 
perfusion of the placenta (Figure 1.1).  
 
 
Figure 1.1 :  Uteroplacental perfusion in normal pregnancy compares to preeclampsia 
(Adapted from Atlas Of Kidney Disease, 2007) 
 
Placenta ischemia leads to release of toxic substance that initiates widespread endothelial cell 
dysfunction and resulted in increased platelet aggregation. This sequential steps resulted in tissue  
and organ hypoperfusion, and kidney injury (Figure 1.2). 
 
 
Figure 1.2 : Pathophysiology of  kidney injury 
(Adapted from Atlas Of Kidney Disease, 2007) 
 
1.4. New biomarkers in detecting renal impairment 
1.4.1. Cystatin C 
Cystatin C is  a cysteine protease inhibitor produced and released at constant rate  by nucleated 
cells. It is freely filtered by the glomerulus and not influenced by race and muscle mass.  
Cystatin C was demonstrated to predict Acute Kidney Injury 1-2 days earlier than the 
conventional methods (Herget-Rosenthal et al., 2000). Unlike creatinine,  Cystatin C serum 
levels are virtually unaffected by age (>1 year), muscle mass, gender and race.  Cystatin C was 
described to be an early predictive biomarker of AKI, higher accuracy compared to serum 
creatinine in emergency department setting (Misra et al., 2003). Patient plasma is required for 
analysis via immunoassays. Urinary Cystatin C assay has also been used for earlier detection of 
kidney injury and need for renal replacement therapy. The mean serum Cystatin C levels reflect 
changes in the GFR in normal pregnancy population and also in the postnatal period (Strevens et 
al., 2002). It has also been shown that serum Cystatin C levels are independent of age, height, 
weight, or blood sugar level (Babay et al., 2005). 
 
1.4.2. Neutrophil Gelatinase-associated Lipocalin (NGAL) 
Human NGAL is a 25 kDa protein that is expressed by neutrophils and various epithelial cells, 
including cells of the proximal convoluted tubule. It is upregulated after ischemic injury. Urinary 
NGAL is a promising biomarker for AKI because it is upregulated within 2 hours of acute renal 
cellular injury. NGAL is normally expressed in low levels in human tissues, including the 
kidney, lung, stomach and colon, the expression is marked in the presence of renal tubular cells 
injury. In preclinical studies, NGAL has been shown to be easily detected in blood and urine in 
early AKI. It has also been used as kidney biomarkers in renal transplant patients (Liangos et al., 
2009). 
 
1.4.3. Kidney Injury Molecule – 1 (KIM-1) 
Kidney injury molecule 1 (KIM-1) is a transmembrane protein overexpressed in proximal tubule 
cells of the kidney in response to ischemic or nephrotoxic injury to human and animal models.  
One study was prospectively evaluated the expression of KIM-1 levels in 103 patients 
undergoing cardiopulmonary bypass surgery. AKI defined as 0.3 mg/dl increase of creatinine  
more common in patients with elevated KIM-1 levels compared with other biomarkers (Liangos 
et al., 2009). Other studies also demonstrated urinary KIM-1 able to differentiate between pre-
renal and renal causes of kidney injury. The sensitivity of specificity of KIM-1 are 99% sensitive 
and 95% specific, however the results obtained is not in pregnant ladies with hypertension.  
 
1.4.4. Interleukin – 18 (IL-18) 
IL-18 is a proinflammatory cytokine activated within the proximal tubule and excreted in urine 
after ischemic kidney injury. One study was demonstrated to compare urinary IL-18 
concentration in patients  with  diagnosis of Acute Tubular Necrosis (ATN) with healthy 
controls. Patients with ATN had markedly increased IL-18 and elevated ratios of urinary IL-18 
to creatinine compared with other group (Parikh et al., 2006) .   
 
1.4.5. The need for rapid and reliable diagnostic test in detecting kidney disease in 
hypertensive pregnancies 
Rapid diagnosis of acute kidney injury in pregnancy will prevent potential adverse outcomes to 
the mother and fetus. Earlier intervention can be initiated to reverse the potential ongoing insult.  
In one study, described mortality between 20-30% in pregnant ladies with acute kidney injury 
(Hou and Peano, 1998). It is important of earlier initiation of dialysis for better control of 
azotemia and improving the overall outcomes (Gammill and Jeyabalan, 2005). However the role 
of prophylactic dialysis in pregnant ladies with acute kidney injury is debatable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HYPOTHESIS
CHAPTER 2  
HYPOTHESIS 
 
We hypothesized that Cystatin C is a reliable test for detection of renal impairment in 
hypertensive pregnancies that carries acceptable  sensitivity and specificity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
OBJECTIVES
CHAPTER 3 
OBJECTIVES 
Objectives : 
  
1. To determine sensitivity and specificity of Cystatin C in comparison to 24 hour urine 
Creatinine clearance in hypertensive pregnancies. 
2. To compare Cystatin C level in hypertensive pregnant lady between 2nd  and 3rd
 
 trimester. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODOLOGY 
CHAPTER 4 
METHODOLOGY 
This section describes the materials and general methods used in this work. Specific methods are 
described in the respective chapters. 
 
4.1. Materials 
4.1.1. Subjects 
This study was approved by the Research Ethics Committee (Human) on 21st 
and funded by short term grant (304/PPSP/6139008) Hospital Universiti Sains Malaysia 
(HUSM). This pilot prospective cross sectional study was conducted in HUSM between January 
2009 and January 2010. Flow chart of the study is shown in Figure 4.1. All  pregnant patients 
beginning with 2
November 2010   
nd
 
 trimester at the age of 16 years old to 55 years old and hypertensives 
including gestational hypertension, chronic hypertension, chronic hypertension with 
superimposed preeclampsia, preeclampsia and unclassified hypertension were included. Verbally 
informed consent was obtained prior to the involvement of the patients into the study followed 
by written consent. Recruitment was done on patients that meet the inclusion and exclusion 
criteria and consented to participate. 
Patients included in this cross-sectional study whom had satisfied the inclusion criteria, were 
informed regarding their involvement in the study and explained regarding the need to collect 5 
mls of blood sample exclusive of other routine blood investigations. They were also required to 
provide 24 hour urine collection sample for the analysis. Blood investigations was taken in serial 
during the 2nd and 3rd
 
 trimester. 64 patients were selected and enrolled in this cross sectional 
study.  
The inclusion and exclusion criteria for the patients were as follows: 
4.1.1.1  Inclusion criteria: 
 Consented for the study 
 Patients beginning from 2nd
gestational hypertension, chronic hypertension, chronic hypertension with superimposed  
 trimester of pregnancy whom are hypertensives including 
preeclampsia, preeclampsia and unclassified hypertension. 
 Age : 16-55 years  
 
4.1.1.2  Exclusion criteria: 
 Hyper/Hypothyroidism 
 Smokers 
 Receiving corticosteroids 
 Suffering from any forms of malignancy 
 
4.1.2. Reagents/Kits 
The reagents were used for the analysis of the blood sample as listed in the product inlet. The 
laboratory analysis was performed and prepared as recommended in the product inlet. The 24 
hour urine creatinine clearance and the reagents are listed in Table 4.1. The Cystatin C reagents 
are as listed in Table 4.2. 
 
Table 4.1 : 24 hour urine creatinine clearance and reagents 
 
 Reagents Working solutions 
R1 Sodium hydroxide 0.20 mol/L 
R2 Picric acid 25mmol/L 
 
Table 4.2 : Cystatin C and control reagents 
Materials  Compositions 
N Cystatin C Reagents A suspension of polystyrene particles coated with 
approximately 0.03 g/L anti-human cystatin C 
from rabbits. 
N Cystatin C Supplementary Reagents A Contains rabbit immunoglobulin  (14 g/L) in 
buffered solution. 
N Cystatin C Supplementary Reagents B Consists of an aqueous solution of polyethylene 
glycolsorbitan monolaureate (85 g/L) and 
polyethylene glycol ether (27 g/L). 
N Cystatin C Control Level 1 and  
N Cystatin C Control Level 2 
Lyophilized polygeline with urine proteins of 
human origin. The concentration of  Cystatin C 
was standardized with reference to purified 
Cystatin C. Once reconstituted, the controls 
contain the Cystatin C concentration as indicated 
on the respective vial label. 
 4.2. Methods 
This study was carried out in HUSM, Kubang Kerian Kelantan. It  was a prospective cross 
sectional study which involved 64 patients and suspected clinically as renal failure related to the 
hypertension in pregnancy. 
 
Patients were seen in antenatal clinic and antenatal wards. Selected patients whom satisfied the 
inclusion criterias were given explanations regarding the study and consent taken. Patients who 
agreed to participate were required to provide blood samples about 5 mls and 24 hour urine 
collection. The blood samples were taken to the Department of Chemical Pathology Laboratory, 
School Of Medical Sciences for analysis. Serum Cystatin C was measured with N Latex Cystatin 
C kit, a particle-enhanced nephelometric immunoassay (PENIA) method, on a fully automated 
BN II nephelometer (Dade Behring Diagnostics). Serum and urine creatinine will be determined 
by a kinetic colorimetric assay on a Hitachi 912 analyser. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
Figure 4.1: Flow chart on the methodology of study  
Perform Serum Cystatin C and other conventional 
Renal Functions Test at 2nd and 3rd trimester 
 
Perform 24 hour Urine  Creatinine Clearance 
 
 
Data collections and Laboratory work 
Results and reports 
Patients recruited from O & G 
clinic and antenatal wards 
n=64 
 
Exclusion criteria : 
 Hyper/Hypothyroidism 
 Cancers 
 Smoking 
 Steroids usage 
 
Inclusion criteria : 
 Consented for the study 
 Patients beginning from 2nd trimester and 
hypertensive i.e : gestational hypertension, 
chronic hypertension, preeclampsia  
 Age 16 – 55 years old 
Statistical Analysis 
4.2.1.Cystatin C 
Patients who were selected for the study were requested for blood sample. About 5mls of blood 
were taken during antenatal clinic or inpatients. They were required to give the blood each in 2nd 
and 3rd
The serum was manually transferred to the sample cups which is small in size.  
 trimester. The blood was sent to the Chemical Pathology Laboratory, HUSM. In the 
laboratory, the blood was run in the Eppendorf Centrifuge 5810 machine to obtain the serum and 
supernatant.  
 
Figure 4.2 : Sample cups           
  
The serum were kept in the freezer in temperature below -17°C before being analyzed . 
The serum sample collection was equilibrated in room temperature with reagent N Latex 
Cystatin C and automatically diluted 1:100 with N Diluent.  
 Figure 4.3 : N latex Cystatin C reagent 
 
 
Analyzing process started by using Dade–Behring Nephelometer Systems and results were 
automatically evaluated . 
 
Figure 4.4 :  Dade Behring analysis machine 
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    Figure 4.5 : Cystatin C process 
CENTRIFUGE MACHINE : EPPENDORF 
CENTRIFUGE 5810 
BLOOD SAMPLE FROM PATIENT 
SERUM 
SAMPLE CUP 
CYSTATIN C ( keep in freezer : 
-17° C as it runs by batches ) 
 
Sample + Reagent ( equilibrate in 
room temperature ) 
Reagent : N Latex Cystatin C 
 
                                                                                        Analyze 
 
 
 
 
 
 
 
 
 
Figure 4.5 : (continue) Cystatin C process 
 
 
 
 
 
 
 
 
 
 
 
Analyzer : Dade–Behring 
Nephelometer Systems 
Automatically diluted 1:100 with N 
Diluent  
Results are automatically evaluated 
